ArticleBioinformation2025
Early continuous positive airway pressure versus surfactant therapy in preterm neonates with respiratory distress.
Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory Distress Syndrome (RDS) remains a major cause of morbidity and mortality in preterm neonates, particularly in resource- limited Level 2 Special Newborn Care Units. Therefore, it is of interest to analyse outcomes of 308 preterm neonates treated with early Continuous Positive Airway Pressure (CPAP) or combined CPAP-surfactant therapy across three gestational age groups. Survival was highest with CPAP alone in moderate and late preterm neonates (31-36 weeks), reaching 84.4%-87.3%. Extremely preterm neonates (27-30 weeks) showed improved outcomes with early selective surfactant plus CPAP, though mortality remained higher due to pulmonary hemorrhage and sepsis. Early CPAP is highly effective for 31-36-week neonates, while extremely preterm infants benefit most from combined CPAP-surfactant therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.